Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.

Pol JG, Bridle BW, Lichty BD.

Methods Mol Biol. 2020;2058:191-211. doi: 10.1007/978-1-4939-9794-7_12.

PMID:
31486039
2.

Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.

McGray AJR, Huang RY, Battaglia S, Eppolito C, Miliotto A, Stephenson KB, Lugade AA, Webster G, Lichty BD, Seshadri M, Kozbor D, Odunsi K.

J Immunother Cancer. 2019 Jul 17;7(1):189. doi: 10.1186/s40425-019-0641-x.

3.

Excipient selection for thermally stable enveloped and non-enveloped viral vaccine platforms in dry powders.

Toniolo SP, Afkhami S, Mahmood A, Fradin C, Lichty BD, Miller MS, Xing Z, Cranston ED, Thompson MR.

Int J Pharm. 2019 Apr 20;561:66-73. doi: 10.1016/j.ijpharm.2019.02.035. Epub 2019 Feb 28.

PMID:
30825554
4.

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.

Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV, Lopez R, LaFrance S, Evelegh C, Denisova G, Parsons R, Millar J, Stoll G, Martin CG, Pomoransky J, Breitbach CJ, Bramson JL, Bell JC, Wan Y, Stojdl DF, Lichty BD, McCart JA.

Oncoimmunology. 2018 Sep 19;8(1):e1512329. doi: 10.1080/2162402X.2018.1512329. eCollection 2019.

5.

Development and applications of oncolytic Maraba virus vaccines.

Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD.

Oncolytic Virother. 2018 Nov 26;7:117-128. doi: 10.2147/OV.S154494. eCollection 2018. Review.

6.

Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Atherton MJ, Stephenson KB, Tzelepis F, Bakhshinyan D, Nikota JK, Son HH, Jirovec A, Lefebvre C, Dvorkin-Gheva A, Ashkar AA, Wan Y, Stojdl DF, Belanger EC, Breau RH, Bell JC, Saad F, Singh SK, Diallo JS, Lichty BD.

Oncoimmunology. 2018 Mar 27;7(7):e1445459. doi: 10.1080/2162402X.2018.1445459. eCollection 2018.

7.

Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages.

Masemann D, Köther K, Kuhlencord M, Varga G, Roth J, Lichty BD, Rapp UR, Wixler V, Ludwig S.

Oncoimmunology. 2018 Feb 12;7(5):e1423171. doi: 10.1080/2162402X.2017.1423171. eCollection 2018.

8.

Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer.

Atherton MJ, Stephenson KB, Nikota JK, Hu QN, Nguyen A, Wan Y, Lichty BD.

Vaccine. 2018 Apr 12;36(16):2181-2192. doi: 10.1016/j.vaccine.2018.02.070. Epub 2018 Mar 12.

PMID:
29544689
9.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.

PMID:
29298865
10.

Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats.

Hummel J, Bienzle D, Morrison A, Cieplak M, Stephenson K, DeLay J, Woods JP, Lichty BD, Bridle BW.

Sci Rep. 2017 Nov 16;7(1):15738. doi: 10.1038/s41598-017-15992-4.

11.

Customized Viral Immunotherapy for HPV-Associated Cancer.

Atherton MJ, Stephenson KB, Pol J, Wang F, Lefebvre C, Stojdl DF, Nikota JK, Dvorkin-Gheva A, Nguyen A, Chen L, Johnson-Obaseki S, Villeneuve PJ, Diallo JS, Dimitroulakos J, Wan Y, Lichty BD.

Cancer Immunol Res. 2017 Oct;5(10):847-859. doi: 10.1158/2326-6066.CIR-17-0102. Epub 2017 Sep 14.

12.

Correction: Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence.

Ananth AA, Tai LH, Lansdell C, Alkayyal AA, Baxter KE, Angka L, Zhang J, de Souza CT, Stephenson KB, Parato K, Bramson JL, Bell JC, Lichty BD, Auer RC.

PLoS One. 2016 Jul 18;11(7):e0159471. doi: 10.1371/journal.pone.0159471. eCollection 2016.

13.

Oncolytic Viruses: Therapeutics With an Identity Crisis.

Breitbach CJ, Lichty BD, Bell JC.

EBioMedicine. 2016 Jul;9:31-36. doi: 10.1016/j.ebiom.2016.06.046. Epub 2016 Jul 2. Review.

14.

Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence.

Ananth AA, Tai LH, Lansdell C, Alkayyal AA, Baxter KE, Angka L, Zhang J, Tanese de Souza C, Stephenson KB, Parato K, Bramson JL, Bell JC, Lichty BD, Auer RC.

PLoS One. 2016 May 19;11(5):e0155947. doi: 10.1371/journal.pone.0155947. eCollection 2016. Erratum in: PLoS One. 2016;11(7):e0159471.

15.

Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.

Bridle BW, Nguyen A, Salem O, Zhang L, Koshy S, Clouthier D, Chen L, Pol J, Swift SL, Bowdish DM, Lichty BD, Bramson JL, Wan Y.

J Immunol. 2016 Jun 1;196(11):4587-95. doi: 10.4049/jimmunol.1600106. Epub 2016 Apr 27.

16.

S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3.

Wang F, Alain T, Szretter KJ, Stephenson K, Pol JG, Atherton MJ, Hoang HD, Fonseca BD, Zakaria C, Chen L, Rangwala Z, Hesch A, Chan ESY, Tuinman C, Suthar MS, Jiang Z, Ashkar AA, Thomas G, Kozma SC, Gale M Jr, Fitzgerald KA, Diamond MS, Mossman K, Sonenberg N, Wan Y, Lichty BD.

Nat Immunol. 2016 May;17(5):514-522. doi: 10.1038/ni.3433. Epub 2016 Apr 4.

17.

Cancer immunology and canine malignant melanoma: A comparative review.

Atherton MJ, Morris JS, McDermott MR, Lichty BD.

Vet Immunol Immunopathol. 2016 Jan;169:15-26. doi: 10.1016/j.vetimm.2015.11.003. Epub 2015 Dec 1. Review.

PMID:
26827834
18.

Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy.

Roy DG, Power AT, Bourgeois-Daigneault MC, Falls T, Ferreira L, Stern A, Tanese de Souza C, McCart JA, Stojdl DF, Lichty BD, Atkins H, Auer RC, Bell JC, Le Boeuf F.

J Control Release. 2015 Dec 28;220(Pt A):210-221. doi: 10.1016/j.jconrel.2015.10.030. Epub 2015 Oct 19.

PMID:
26482080
19.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, Kirn DH, Raptis L, Sad S, Atkins H, Huh MS, Diallo JS, Lichty BD, Ilkow CS, Le Boeuf F, Addison CL, McCart JA, Bell JC.

Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub 2015 Jul 23.

20.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.

PMID:
25894825
21.

Microvesicles: ubiquitous contributors to infection and immunity.

Lai FW, Lichty BD, Bowdish DM.

J Leukoc Biol. 2015 Feb;97(2):237-45. doi: 10.1189/jlb.3RU0513-292RR. Epub 2014 Dec 3. Review.

PMID:
25473096
22.

Going viral with cancer immunotherapy.

Lichty BD, Breitbach CJ, Stojdl DF, Bell JC.

Nat Rev Cancer. 2014 Aug;14(8):559-67. doi: 10.1038/nrc3770. Epub 2014 Jul 3. Review.

PMID:
24990523
23.

Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL.

Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19.

24.

Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

Zhang J, Tai LH, Ilkow CS, Alkayyal AA, Ananth AA, de Souza CT, Wang J, Sahi S, Ly L, Lefebvre C, Falls TJ, Stephenson KB, Mahmoud AB, Makrigiannis AP, Lichty BD, Bell JC, Stojdl DF, Auer RC.

Mol Ther. 2014 Jul;22(7):1320-1332. doi: 10.1038/mt.2014.60. Epub 2014 Apr 3.

25.

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL.

Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9.

26.

Maraba virus as a potent oncolytic vaccine vector.

Pol JG, Zhang L, Bridle BW, Stephenson KB, Rességuier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD.

Mol Ther. 2014 Feb;22(2):420-429. doi: 10.1038/mt.2013.249. Epub 2013 Oct 25.

27.

Evolution of oncolytic viruses: novel strategies for cancer treatment.

Atherton MJ, Lichty BD.

Immunotherapy. 2013 Nov;5(11):1191-206. doi: 10.2217/imt.13.123. Review. Erratum in: Immunotherapy. 2014 May;6(5):657-8.

PMID:
24188674
28.

Human coronavirus OC43 nucleocapsid protein binds microRNA 9 and potentiates NF-κB activation.

Lai FW, Stephenson KB, Mahony J, Lichty BD.

J Virol. 2014 Jan;88(1):54-65. doi: 10.1128/JVI.02678-13. Epub 2013 Oct 9.

29.

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines.

Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, Bramson JL, Wan Y.

Oncoimmunology. 2013 Aug 1;2(8):e26013. Epub 2013 Aug 27.

30.

Panorama from the oncolytic virotherapy summit.

Pol JG, Marguerie M, Arulanandam R, Bell JC, Lichty BD.

Mol Ther. 2013 Oct;21(10):1814-8. doi: 10.1038/mt.2013.207. No abstract available.

31.

Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses.

Zhang L, Bridle BW, Chen L, Pol J, Spaner D, Boudreau JE, Rosen A, Bassett JD, Lichty BD, Bramson JL, Wan Y.

Blood. 2013 Mar 28;121(13):2432-9. doi: 10.1182/blood-2012-06-438481. Epub 2013 Jan 16.

32.

HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.

Bridle BW, Chen L, Lemay CG, Diallo JS, Pol J, Nguyen A, Capretta A, He R, Bramson JL, Bell JC, Lichty BD, Wan Y.

Mol Ther. 2013 Apr;21(4):887-94. doi: 10.1038/mt.2012.265. Epub 2013 Jan 8.

33.

Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity.

Jeyanathan M, Damjanovic D, Shaler CR, Lai R, Wortzman M, Yin C, Zganiacz A, Lichty BD, Xing Z.

Mucosal Immunol. 2013 May;6(3):612-25. doi: 10.1038/mi.2012.103. Epub 2012 Nov 7.

PMID:
23131783
34.

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, Diallo JS, Arulanandam R, Le Boeuf F, Garson K, Vanderhyden BC, Stojdl DF, Lichty BD, Atkins HL, Parato KA, Bell JC, Auer RC.

Mol Ther. 2012 Sep;20(9):1791-9. doi: 10.1038/mt.2012.128. Epub 2012 Jul 3.

35.

IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.

Chenoweth MJ, Mian MF, Barra NG, Alain T, Sonenberg N, Bramson J, Lichty BD, Richards CD, Ma A, Ashkar AA.

J Immunol. 2012 May 1;188(9):4149-57. doi: 10.4049/jimmunol.1101883. Epub 2012 Mar 23.

36.

ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.

Rintoul JL, Lemay CG, Tai LH, Stanford MM, Falls TJ, de Souza CT, Bridle BW, Daneshmand M, Ohashi PS, Wan Y, Lichty BD, Mercer AA, Auer RC, Atkins HL, Bell JC.

Mol Ther. 2012 Jun;20(6):1148-57. doi: 10.1038/mt.2011.301. Epub 2012 Jan 24.

37.

Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity.

Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD.

Cancer Gene Ther. 2012 Apr;19(4):238-46. doi: 10.1038/cgt.2011.81. Epub 2011 Dec 9.

PMID:
22158521
38.

Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.

Leveille S, Goulet ML, Lichty BD, Hiscott J.

J Virol. 2011 Dec;85(23):12160-9. doi: 10.1128/JVI.05703-11. Epub 2011 Sep 14.

39.

Strategies to enhance viral penetration of solid tumors.

Smith E, Breznik J, Lichty BD.

Hum Gene Ther. 2011 Sep;22(9):1053-60. doi: 10.1089/hum.2010.227. Epub 2011 May 19. Review.

PMID:
21443415
40.

Targeting tumor vasculature with an oncolytic virus.

Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshmand M, Parato K, Stanford MM, Lichty BD, Fenster A, Kirn D, Atkins H, Bell JC.

Mol Ther. 2011 May;19(5):886-94. doi: 10.1038/mt.2011.26. Epub 2011 Mar 1.

41.

IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells.

Boudreau JE, Stephenson KB, Wang F, Ashkar AA, Mossman KL, Lenz LL, Rosenthal KL, Bramson JL, Lichty BD, Wan Y.

Cancer Res. 2011 Apr 1;71(7):2497-506. doi: 10.1158/0008-5472.CAN-10-3025. Epub 2011 Feb 9.

42.

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy.

Sobol PT, Boudreau JE, Stephenson K, Wan Y, Lichty BD, Mossman KL.

Mol Ther. 2011 Feb;19(2):335-44. doi: 10.1038/mt.2010.264. Epub 2010 Nov 30.

43.

Potentiating cancer immunotherapy using an oncolytic virus.

Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y.

Mol Ther. 2010 Aug;18(8):1430-9. doi: 10.1038/mt.2010.98. Epub 2010 Jun 15.

44.

FimH can directly activate human and murine natural killer cells via TLR4.

Mian MF, Lauzon NM, Andrews DW, Lichty BD, Ashkar AA.

Mol Ther. 2010 Jul;18(7):1379-88. doi: 10.1038/mt.2010.75. Epub 2010 May 4.

45.

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, MacTavish H, Waite K, Falls T, Wang J, Brown R, Blanchard JE, Brown ED, Kirn DH, Hiscott J, Atkins H, Lichty BD, Bell JC.

Mol Ther. 2010 Jun;18(6):1123-9. doi: 10.1038/mt.2010.67. Epub 2010 Apr 13.

46.

Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen.

Bridle BW, Li J, Jiang S, Chang R, Lichty BD, Bramson JL, Wan Y.

J Immunol. 2010 Apr 15;184(8):4269-75. doi: 10.4049/jimmunol.0901447. Epub 2010 Mar 17.

47.

Synergistic interaction between oncolytic viruses augments tumor killing.

Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, Kanji F, Auer R, Brown CW, Lichty BD, Parato K, Atkins H, Kirn D, Bell JC.

Mol Ther. 2010 May;18(5):888-95. doi: 10.1038/mt.2010.44. Epub 2010 Mar 16.

48.

Combining oncolytic virotherapy and tumour vaccination.

Bridle BW, Hanson S, Lichty BD.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):143-8. doi: 10.1016/j.cytogfr.2010.02.009. Epub 2010 Mar 11. Review.

PMID:
20226716
49.

Intelligent design: combination therapy with oncolytic viruses.

Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA.

Mol Ther. 2010 Feb;18(2):251-63. doi: 10.1038/mt.2009.283. Epub 2009 Dec 22. Review.

50.

Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells.

Li B, Lei Z, Lichty BD, Li D, Zhang GM, Feng ZH, Wan Y, Huang B.

Cancer Immunol Immunother. 2010 Feb;59(2):313-21. doi: 10.1007/s00262-009-0752-1.

PMID:
19680649

Supplemental Content

Loading ...
Support Center